Murine cytomegalovirus inactivated by sodium periodate is innocuous and immunogenic in mice and protects them against death and infection

Vaccine

Volumn 14, Issue 17-18, 1996, Pages 1686-1694

  Geoffroy, Fabrice ^a,c   Moachon, Nicolas ^a   Rodwell, John ^b   Quash, Gerard A ^a  

^a UNIVERSITÉ LYON 1   (France)

^b Cytogen Corporation   (United States)

^c Pasteur Mérieux Connaught S ^*  (France)

Author keywords

murine cytomegalovirus; sodium periodate; viral inactivation

Indexed keywords

CYTOMEGALOVIRUS VACCINE; PERIODATE SODIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; FEMALE; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS INACTIVATION;

ANIMALS; ANTIBODIES, VIRAL; CELLS, CULTURED; CYTOMEGALOVIRUS INFECTIONS; FEMALE; IMMUNIZATION; KINETICS; MICE; MICE, INBRED BALB C; MUROMEGALOVIRUS; PERIODIC ACID; VACCINES, INACTIVATED; VIRULENCE; VIRUS LATENCY; VIRUS REPLICATION;

EID: 0030481434     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(96)00116-8     Document Type: Article

References (32)

1. 1 Gehrz, R.C. Human cytomegalovirus: biology and clinical perspectives. Adv. Pediatrics 1991, 38, 203-232
2. 2 Plotkin, S.A. Vaccines for varicella-zoster virus and cytomegalovirus: recent progress. Science 1994, 265, 1383-1385
3. 3 Hudson, J.B. The murine cytomegalovirus as a model for the study of viral pathogenesis and persistent infections. Arch. Virol. 1979, 62, 1-20
4. 4 Elek, S.D. and Stern, H. Development of a vaccine against mental retardation caused by cytomegalovirus infection in utero. Lancet 1974, 1, 1-5
5. 5 Plotkin, S.A., Furukawa, T., Zygraich, N. and Huygelen, C. Candidate cytomegalovirus strain for human vaccination. Infect. Immun. 1975, 12, 521-527
6. 6 Howard, R.J. and Balfour, H.H.J. Prevention of morbidity and mortality of wild murine cytomegalovirus by vaccination with attenuated cytomegalovirus. Proc. Soc. Exp. Biol. Med. 1977, 156, 365-368
7. 7 Gonczol, E. and Plotkin, S. Progress in vaccine development for prevention of human cytomegalovirus infection. Curr. Top. Microbiol. Immunol. 1990, 154, 255-274
8. 8 Adler S.P., Starr, S.E., Plotkin, S. A., Hempfling, S. H., Buis, J., Manning, M. L. and Best, A.M., Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age. J. Infect. Dis., 1995, 171, 26-32
9. 9 Jordan, M.C. Adverse effects of cytomegalovirus vaccination in mice. J. Clin. Invest. 1980, 65, 798-803
10. 10 Britt, W., Fay, J., Seals, J. and Kensil, C. Formulation of an immunogenic human cytomegalovirus vaccine: responses in mice. J. Infect. Dis. 1995, 171, 18-25
11. 11 Cranage, M.P., Kouzarides, T., Bankier, A., Satchwell, S., Weston, K., Tomlinson, P. and Barrell, B. Identification of the human cytomegalovirus glycoprotein B gene and induction of neutralizing antibodies via its expression in recombinant vaccinia virus. EMBO J. 1986, 5, 3057-3063
12. 12 Gonczol, E., DeTaisne, C., Hirka, G., Berencsi, K., Lin, W., Paoletti, E. and Plotkin, S.A. High expression of human cytomegalovirus (HCMV)-gB protein in cells infected with a vaccinia-gB recombinant: the importance of the gB protein in HCMV immunity. Vaccine 1991, 9, 631-637
13. 13 Marshall, G.S., Ricciardi, R.P., Rando, R.F., Puck, J., Ge, R., Plotkin, S.A. and Gonczol, E. An adenovirus recombinant that expresses the human cytomegalovirus major envelope glycoprotein and induces neutralizing antibodies. J. Infect. Dis. 1990, 162, 1177-1181
14. 14 Britt, W.J., Vugler, L. and Stephens, E.B. Induction of complement dependent and independant neutralizing antibodies by recombinant-derived human cytomegalovirus gp55-116 (gB). J. Virol. 1988, 62, 3309-3318
15. 15 Berencsi, K., Rando, R.F., DeTaisne, C., Paoletti, E., Plotkin, S.A. and Gonczol, E. Murine cytotoxic T cell response specific for human cytomegalovirus glycoprotein B (gB) induced by adenovirus and vaccinia virus recombinants expressing gB. J. Gen. Virol. 1993, 74, 2507-2512
16. 16 Gonczol, E., Berencsi, K., Pincus, S., Endresz, V., Méric, C., Paoletti, E. and Plotkin, S.A. Preclinical evaluation of an ALVAC (canarypox)-human cytomegalovirus glycoprotein B vaccine candidate. Vaccine 1995, 13, 1080-1085
17. 17 Jonjic, S., Del-Val, M., Keil, G.M., Reddehase, M.J. and Koszinowski, U.H. A nonstructural viral protein expressed by a recombinant vaccinia virus protects against lethal cytomegalovirus infection. J. Virol. 1988, 62, 1653-1658
18. 18 Del-Val, M., Schlicht, H.J., Volkmer, H., Messerle, M., Reddehase, M.J. and Koszinowski, U.H. Protection against lethal cytomegalovirus infection by a recombinant vaccine containing a single nonameric T-cell epitope. J. Virol. 1991, 65, 3641-3646
19. 19 Tolpin, M.D., Starr, S.E., Arbeter, A.M. and Plotkin, S.A. Inactivated mouse cytomegalovirus vaccine: preparation, immunogenicity and protective effect. J. Infect. Dis. 1980, 142, 569-574
20. 20 Quash G.A., Rodwell J.D., McKearn T.J. and Ripoll J.P. October 1990. U.S. patent 4,965,069.
21. 21 Dreesman, G.R. and Suriano, J.R. Alteration of adenovirus antigenic sites and infectivity by periodate oxidation. Virology 1976, 69, 700-709
22. 22 Ogier, G., Michal, Y., Thomas, V., Quash, G. and Rodwell, J. Inhibition of type 5 adenovirus by periodate oxidation. Arch. Virol. 1994, 135, 43-60
23. 23 Geoffroy, F., Ogier, G., Chantepie, J. and Quash, G. Inactivation of human cytomegalovirus by sodium periodate oxidation. Arch. Virol. 1994, 135, 61-74
24. 24 Ebeling, A., Keil, G.M., Knust, E. and Koszinowski, U.H. Molecular cloning and physical mapping of murine cytomegalovirus DNA. J. Virol. 1983, 47, 421-433
25. 25 Osborn, J.E. and Walker, D.L. Enhancement of infectivity of murine cytomegalovirus in vitro by centrifugal inoculation. J. Virol. 1968, 2, 853-858
26. 26 Thomas, V., El Alaoui, S., Roch, A.M. and Quash, G.A. A novel covalent enzyme-linked immunoassay (CELIA) for simultaneously measuring free and immune complex bound antibodies with defined specificity. II. Application to immune complexes containing viral antigens in human sera. J. Immunol. Methods 1990, 133, 13-19
27. 27 Mayo, D.R., Armstrong, J.A. and Ho, M. Reactivation of murine cytomegalovirus by cyclophosphamide. Nature 1977, 267, 721-723
28. 28 Jordan, M.C., Shanley, J.D. and Stevens, J.G. Immunosuppression reactivates and disseminates latent murine cytomegalovirus. J. Gen. Virol. 1977, 37, 419-423
29. 29 Perrin, P. and Morgeaux, S. Inactivation of DNA by β-propiolactone. Biologicals 1995, 23, 207-211
30. 30 Duque, H., Marshall, R.L., Israel, B.A. and Letchworth, G.J. Effects of formalin inactivation on bovine herpes virus-1 glycoproteins and antibody response elicited by formalin-inactivated vaccines in rabbits. Vaccine 1989, 7, 513-520
31. 31 Ferguson, M., Wood, D.J. and Minor, P.D. Antigenic structure of poliovirus in inactivated vaccines. J. Gen. Virol. 1993, 74, 685-690
32. 32 Reddehase, M.J., Balthesen, M., Rapp, M., Jonjic, S., Pavic, I. and Koszinowski, U.H. The conditions of primary infection define the load of latent viral genome in organs and the risk of reccurent cytomegalovirus disease. J. Exp. Med. 1994, 179, 185-193